HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Cost estimates of chronic hepatitis B virus for the Brazilian unified health system in 2005].

AbstractBACKGROUND:
Chronic Hepatitis B Virus (CHBV) is a disease that places a large financial burden on healthcare systems and society.
OBJECTIVE:
The aim of this study was to estimate patient management patterns, and associated medical resource utilization and expenses, for each of the four stages of chronic HBV infection in the public unified healthcare system settings, in 2005. METHODS. An expert panel comprised of ten physicians, leading specialists in hepatology and infectious diseases, was convened to obtain information regarding management of CHBV patients in Brazil. Expense inputs were mainly obtained from government fee schedules and pharmaceutical price tables. Costs were estimated under the perspective of the public health system. Data were analyzed using Windows SPSS version 12.0.
RESULTS:
Estimated patient expenses were calculated for the four stages of CHBV infection. The estimated annual expenses per patient were: R$ 980.89 (US$ 392) for chronic hepatitis B with no cirrhosis and without antiviral therapy; R$ 1,243.17 (US$ 496) for compensated cirrhosis without antiviral therapy; R$ 22,022.61 (US$ 8809) for decompensated cirrhosis; R$ 4,764.95 (US$ 1,905) for hepatocellular carcinoma; and R$ 87,372.60 (US$ 34,948) for liver transplant.
CONCLUSION:
Estimated expenses associated with drugs and procedures represented the main components of the expenses of CHBV infection. In this model, expenses increase dramatically as the disease progresses to more advanced stages, suggesting that over the long term delaying progression may reduce costs.
AuthorsAdauto Castelo, Mario G Pessôa, Tânia C B B Barreto, Marcia R D Alves, Denizar Vianna Araújo
JournalRevista da Associacao Medica Brasileira (1992) (Rev Assoc Med Bras (1992)) 2007 Nov-Dec Vol. 53 Issue 6 Pg. 486-91 ISSN: 0104-4230 [Print] Brazil
Vernacular TitleEstimativas de custo da hepatite crônica B no sistema único de saúde Brasileiro em 2005.
PMID18157360 (Publication Type: English Abstract, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
Topics
  • Ambulatory Care (economics)
  • Antiviral Agents (economics, therapeutic use)
  • Brazil
  • Costs and Cost Analysis
  • Delivery of Health Care (economics, statistics & numerical data)
  • Disease Progression
  • Health Care Costs
  • Hepatitis B, Chronic (economics, therapy)
  • Hospitalization (economics)
  • Humans
  • Liver Cirrhosis (economics, therapy)
  • Liver Transplantation (economics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: